Skip to Main Content

Boston-based biotech investor Omega Funds now has $438 million more to spend. The company announced Wednesday that it completed its sixth and largest-ever venture capital investment fundraising effort.

The firm’s previous investments include Gossamer Bio, Juno Therapeutics, and Editas Medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED